Neuronetics announced that Health Care Service Corporation, HCSC, has expanded access to TMS for adolescents 15 and older with major depressive disorder, MDD. This policy parallels the recent clearance by the Food and Drug Administration for NeuroStar TMS Therapy as a first-line add-on treatment for this age group. “This milestone policy by HCSC is a testament to the growing recognition that our young people need earlier access to proven mental health treatments like NeuroStar TMS,” stated Keith J. Sullivan, President and CEO of Neuronetics, Inc. “We commend HCSC for their leadership in patient access, as well as our NeuroStar providers and Health Policy team for their advocacy to create positive change for mental health.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
- Neuronetics announces additional payors have updates their TMS coverage
- Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
- Neuronetics releases softwaare upgrades to elevate patient care
- NeuroStar® Releases Software Upgrades to Elevate Patient Care